Steroid-induzierte osteoporose: Pathogenese und therapeutische konsequenzen

Acta Medica Austriaca

Volumn 27, Issue 1, 2000, Pages 23-26

  Kirchgatterer, A ^a   Aschl, G ^b   Knoflach, P ^b  

^a I Interne Abteilung   (Austria)

^b NONE

Author keywords

Bisphosphonates; Calcium; Osteoporosis; Steroids; Vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; DEXAMETHASONE; ESTROGEN; PREDNISOLONE; PREDNISONE; PROGESTERONE; STEROID; TRIAMCINOLONE; VITAMIN D;

DIET SUPPLEMENTATION; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; OSTEOBLAST; OSTEOPOROSIS; PATHOGENESIS; REVIEW; RISK ASSESSMENT; STEROID THERAPY;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; STEROIDS;

EID: 85046526438     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-2571.2000.00105.x     Document Type: Article

References (38)

1. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, Tugwell P, Gordon M, Steele M, Webber C, Goldsmith CH: Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow-up. J Rheumatol 1996;23:995-1000.
2. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Louis-George SM, Tenenhouse A, Chines AA: Intermittent etidronat therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-387.
3. Adachi JD, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A: Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994;21:1922-1926.
4. Adinoff AD, Hollister JR: Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-268.
5. American College of Rheumatology Task Force on Osteoporosis Guidelines: Recommendations for the prevention and Treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumat 1996;39:1791-1801.
6. Askari A, Vignos PJ Jr, Moskowitz RW: Steroid myopathy in connective tissue disease. Am J Med 1976;61:485-492.
7. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C: Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-233.
8. 3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996;125:961-968.
9. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA: Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-882.
10. Compston JE, Cooper C, Kanis JA: Bone densitometry in clinical practice. Br Med J 1995;310:1507-1510.
11. Consensus Development Conference: Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-650.
12. Curtiss PH, Clark WS, Herndon CH: Vertebral fractures resulting from prolonged cortisone and corticotrophin therapy. J Am Med Ass 1954; 156: 467-469.
13. Eastell R, on behalf of a UK Consensus Group Meeting on Osteoporosis: Management of corticosteroid-induced osteoporosis. J Int Med 1995; 237:439-447.
14. Fleisch H: New bisphosphonates in osteoporosis. Osteoporos Int 1993; 3:Suppl 2:15-22.
15. Guaydier-Souquieres G, Kotzki PO, Sabatier JP, Basse-Cathalinat B, Loeb G: In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Osteoporos Int 1996;6:171-177.
16. Hall GM, Daniels M, Doyle DV, Spector TD: Effect of hormone replacement therapy on bone mass in rheumatoid patients treated with and without steroids. Arthritis Rheum 1994;37:1499-1505.
17. Harper KD, Weber TJ: Secondary osteoporosis. Diagnostic considerations. Endocrinol Metabol Clin North Amer 1998;27:325-348.
18. Healey JA, Paget SA, Williams-Russo P, Szatrowski TP, Schneider R, Spiera H, Mitnick H, Ales K, Schwartzberg P: A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996;58:73-80.
19. Lane NE, Lukert B: The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metabol Clin North Amer 1998;27:465-483.
20. Luengo M, Pons F, Martinez de Osaba MJ, Picado C: Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 1994 49:1099-1102.
21. Lukert BP, Johnson BE, Robinson RG: Estrogen and progesteron replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1063-1069.
22. Lukert BP, Raisz LG: Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-364.
23. Melton LJ; Chrischilles EA, Cooper C, Lane AW, Riggs BL: How many women have osteoporosis? J Bone Mineral Res 1992;9:1005-1010.
24. Michel BA, Bloch DA, Fries JF: Predictors of fracture in early rheumatoid arthritis. J Rheumatol 1991;18:804-808.
25. Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G: Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991;49:71-76.
26. Peat ID, Healy S, Reid DM, Ralston SH: Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis 1995;54:66-68.
27. Ray NF, Chan JK, Thamer M, Melton LJ: Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation: J Bone Mineral Res 1997;12:24-35.
28. Reid IR, King AR, Alexander CJ, Ibbertson HK: Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Lancet 1988;1:143-146.
29. Reid IR, Wattie DJ, Evans MC, Stapleton JP: Testosteron therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156:1173-1177.
30. Reid IR: Glucocorticoid osteoporosis - mechanism and management. Eur J Endocrinol 1997;137:209-217.
31. Riggs BL, Melton LJ: The prevention and treatment of osteoporosis. N Engl J Med 1992 327:620-627.
32. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG, for the Glucocorticoid-induced Osteoporosis Intervention Study Group: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-299.
33. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J: Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-1752.
34. Schmeiser-Rieder A: Persönliche Mitteilung. Institut für Sozialmedizin, Universität Wien.
35. Tobias JH: Management of steroid-induced osteoporosis: what is the current state of play? Rheumatology 1999;38:198-201.
36. Vogelsang H, Ferenci P, Woloszczuk W, Resch H, Herold H, Frotz S, Gangl A: Bone disease in vitamin D-deficient patients with Crohn's disease: Dig Dis Sci 1989;34:1094-1099.
37. Walsh LJ, Wong CA, Pringle M, Tattersfield AE: Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. Br Med J 1996;313:344-346.
38. World Health Organisation: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994, No. 843.